IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9856216 B1

PDFFull Text
Date of Patent:
Jan. 02, 2018

Filed:

Apr. 21, 2016

Compounds as tnik, ikkε and tbk1 inhibitors and pharmaceutical composition comprising same

Applicant:

Green Cross Corporation, Yongin-si, Gyeonggi-do, KR;

Inventors:

Soongyu Choi, Yongin-si, KR;

Eun-Jung Park, Yongin-si, KR;

Hee Jeong Seo, Yongin-si, KR;

Younggyu Kong, Yongin-si, KR;

Ickhwan Son, Yongin-si, KR;

Sang-ho Ma, Yongin-si, KR;

Man-Young Cha, Yongin-si, KR;

Mi-Soon Kim, Yongin-si, KR;

Kisoo Park, Yongin-si, KR;

Assignee:

GREEN CROSS CORPORATION, Yongin-si, KR;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Bruck Kifle

Int. Cl.
CPC ...
C07D 209/14 (2006.01); C07D 209/48 (2006.01); C07D 209/46 (2006.01); C07D 417/04 (2006.01); C07D 403/04 (2006.01); C07D 401/04 (2006.01); C07D 403/14 (2006.01); C07D 409/12 (2006.01); C07D 405/12 (2006.01); C07D 409/04 (2006.01); C07D 413/04 (2006.01); C07D 409/14 (2006.01); C07D 403/12 (2006.01); C07D 405/06 (2006.01); C07D 409/06 (2006.01); C07D 471/04 (2006.01); C07D 217/24 (2006.01); C07D 401/12 (2006.01);
U.S. Cl.
CPC ...
C07D 209/46 (2013.01); C07D 217/24 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/06 (2013.01); C07D 405/12 (2013.01); C07D 409/04 (2013.01); C07D 409/06 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01);
Abstract

Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

Find Patent Forward Citations

Loading…